- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01706848
Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound (PMCS EURO HEAL)
May 24, 2014 updated by: Halscion, Inc.
A Post Market Clinical Study Evaluating the Safety, Device Performance and Possible Emergent Risks of Celotres in the Improvement of Wound Healing and the Resulting Scar Consequences Following Suturing of a Wound
The objective of the study is to actively gather additional information on safety, device performance and possible emergent risks following the use of Celotres in a post-market setting when used to improve wound healing and the resulting scar consequences following suturing of a wound.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Katowice, Poland
- Angelius Szpital Proviat
-
Krakow, Poland
- Oddzial Leczenia Oparzen Chirugil Plastysznej
-
Warsaw, Poland
- Wojskowy Oddzial Kliniczny ChirurgiiPlastycznej
-
-
-
-
-
Birmingham, United Kingdom, B15 3SJ
- The Westbourne Center
-
Brentwood, United Kingdom, CM15 8EH
- Brentwood Hospital
-
London, United Kingdom, W1G9LG
- Plastic Surgery W1 Ltd, Suite 1
-
Newcastle Upon Tyne, United Kingdom, NE1 4LP
- Royal Victoria Infirmary
-
Norwich, United Kingdom, NR4 7UY
- Norfolk and Norwich University Hospital
-
Swansea, United Kingdom, SA6 6NL
- Morriston Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients electing to undergo a surgical procedure;
- Patients able and willing to give written informed consent
Exclusion Criteria:
- Patients with a known or potential risk of allergy or sensitivity to products or substances containing porcine gelatin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Celotres
Scar halves randomized to treatment with device, opposite side treated per standard of care.
|
Surgical procedure will be performed as per the standard of care.
Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
|
Active Comparator: Standard surgical wound closure
Scar halves randomized to treatment with device, opposite side treated per standard of care.
|
Surgical procedure will be performed as per the standard of care.
Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Assessed at treatment, suture removal, Months 1, 3, 6, 9 and 12
|
Safety as defined by the incidence of device related adverse events.
|
Assessed at treatment, suture removal, Months 1, 3, 6, 9 and 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness
Time Frame: Assessed at Months 1, 3, 6, 9 and 12
|
Patient and Observer Scar Assessment Scale (POSAS)
|
Assessed at Months 1, 3, 6, 9 and 12
|
Device Performance Evaluation
Time Frame: Assessed at Day 1
|
Questions related to packaging integrity and successful administration of product as assessed by the Principal Investigator
|
Assessed at Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Venkat Ramakrishnan, MD, Brentwood Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
October 3, 2012
First Submitted That Met QC Criteria
October 12, 2012
First Posted (Estimate)
October 15, 2012
Study Record Updates
Last Update Posted (Estimate)
May 28, 2014
Last Update Submitted That Met QC Criteria
May 24, 2014
Last Verified
August 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- HAL-0297
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scar
-
University of California, DavisCompletedLinear Scar | Zigzag ScarUnited States
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Wake Forest University Health SciencesCompleted
-
Medstar Health Research InstituteActive, not recruitingBurn Scar | Scar | Skin Graft ScarUnited States
-
Iran University of Medical SciencesRecruitingDry Needling | Scar Tissue | Hypertrophic Scar | Hypertrophic Surgical Scar | Hypertrophic Scar of Upper Arm (Disorder)United States, Iran, Islamic Republic of
-
University of PittsburghUnited States Department of DefenseTerminatedBurn Scar | Restrictive Scar Contracture | Restrictive Hypertrophic Scar | Burn Scar ContracturesUnited States
-
Maternal and Child Health Hospital of FoshanWithdrawn
-
Lumenis Be Ltd.Terminated
-
Assaf-Harofeh Medical CenterNot yet recruiting
-
Maternal and Child Health Hospital of FoshanWithdrawn
Clinical Trials on Celotres
-
Halscion, Inc.Completed